OCT 6·SEC EDGARLow
Krempa David sold $229K of ETON
Krempa David (Chief Business Officer) sold 4,166 shares of Eton Pharmaceuticals, Inc. (ETON) at $55.07 ($0.23M total) on 2026-10-06.
StockNASDAQ · US · USDHealthcare · Drug Manufacturers - Specialty & Generic
$ETON
Eton Pharmaceuticals, Inc.
AlphAI earnings readSecond Quarter 2026 · AUG 13Record revenue, with Q2 2026 product sales of $37.6 million, representing 99% growth over Q2 2025; raising 2026 revenue guidance to exceed $145 million.Verdict: strongRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $ETONvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $ETON in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $229K 1 txs
Krempa David1× · $229K
10b5-1 share of filings0%
Top stories · $ETONMore →
SEP 28·rttnews.com
Eton Relaunches IMPAVIDO In U.S., Expands Patient Access Programs
Eton Pharmaceuticals (ETON) announced the U.S. launch of IMPAVIDO, a treatment for leishmaniasis. The company acquired exclusive rights and integrated it into its Eton Cares patient support platform, offering co-pay assistance and expanded access programs. ETON stock closed at $57.68 on Friday, down 3.04%.
SEP 28·SEC EDGAR 8-K
Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules
Eton Pharmaceuticals, Inc. (ETON) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO ® (miltefosine) Capsules ● Eton Pharmaceuticals now holds exclusive commercialization rights for IMPAVIDO in the United States ● Eton has integrated full Eton Cares® patient support, including $0
ETON sentiment & insider activity
Recent ETON coverage spans insider activity, earnings and technology.
In the last 30 days, ETON insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($229K). The most active reporter was Krempa David, Chief Business Officer, with 1 filing.
What's driving ETON
The insider sale may signal modest negative sentiment, but the amount is small relative to market cap.
The launch adds a new revenue stream in the leishmaniasis treatment market.
The launch adds a new revenue stream in a rare‑disease market and expands patient support services.
Higher margins and guidance support upside.
The insider sale may signal reduced confidence and could pressure the share price in the short term.
AlphAI scores every news story that mentions ETON with an AI model for sentiment and relevance, and aggregates insider trades from Eton Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $ETON
Score
Krempa David sold $229K of ETON
Krempa David (Chief Business Officer) sold 4,166 shares of Eton Pharmaceuticals, Inc. (ETON) at $55.07 ($0.23M total) on 2026-10-06.
1 min readEton Relaunches IMPAVIDO In U.S., Expands Patient Access Programs
Eton Pharmaceuticals (ETON) announced the U.S. launch of IMPAVIDO, a treatment for leishmaniasis. The company acquired exclusive rights and integrated it into its Eton Cares patient support platform, offering co-pay assistance and expanded access programs. ETON stock closed at $57.68 on Friday, down 3.04%.
2 min readEton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules
Eton Pharmaceuticals, Inc. (ETON) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO ® (miltefosine) Capsules ● Eton Pharmaceuticals now holds exclusive commercialization rights for IMPAVIDO in the United States ● Eton has integrated full Eton Cares® patient support, including $0
2 min readB. Riley’s Top Biotech Picks Ahead of 3Q26 Earnings Season
B. Riley analyst Mayank Mamtani highlighted top biotech picks ahead of 3Q26 earnings, including Axsome Therapeutics (AXSM), Cytokinetics (CYTK), Eton Pharmaceuticals (ETON), Harrow (HROW), TG Therapeutics (TGTX), and Zymeworks (ZYME). The analyst provided price targets and revenue projections for each, noting macroeconomic challenges for small and mid-cap biotech stocks.
3 min readMAIER PAUL V sold $3.0M of ETON
MAIER PAUL V sold 50,000 shares of Eton Pharmaceuticals, Inc. (ETON) at an average of $59.07 ($58.64–$61.77, $2.95M total) across 3 trades on 2026-08-28.
1 min read
Jim Cramer Explains Mad Money Caller How to Handle Eton Pharmaceuticals (ETON)
Eton Pharmaceuticals (ETON) stock has surged from $30 to over $60, driven by record Q2 sales of $37.6M (up 99% YoY) and adjusted EPS of $0.43. Jim Cramer advised taking partial profits. Management raised 2026 revenue guidance to over $145M but faces risks like gross margin compression and insider selling.
2 min readEton's Galzin TM And False Ad Suit Survives Dismissal Bid
Eton Pharmaceuticals can proceed with a lawsuit against Extreme V, alleging trademark infringement and false advertising. The company claims Extreme V marketed a dietary supplement as a treatment for Wilson disease. A Michigan federal judge denied Extreme V's motion to dismiss the case.
1 min readKrempa David sold $1.6M of ETON
Krempa David (Chief Business Officer) sold 25,000 shares of Eton Pharmaceuticals, Inc. (ETON) at $65.07 ($1.63M total) on 2026-08-24.
1 min readEton Pharmaceuticals (ETON) Returns To Profit As Valuation Debate Gets Harder To Ignore
Eton Pharmaceuticals (ETON) reported Q2 earnings with a return to profitability and raised full-year 2026 revenue guidance to at least $145M. The stock has seen significant gains, with a 30-day return of 49.03% and a 1-year return of 266.88%. Analysts' consensus price target is $45.67, suggesting a 39% overvaluation, but a DCF model estimates a fair value of $285.41. Risks include pricing pressure and regulatory setbacks.
2 min read
Eton Pharmaceuticals (ETON) Q2 2026 Earnings Call Transcript
Eton Pharmaceuticals (ETON) reported Q2 2026 revenue of $37.6M, up 99% YoY, driven by HEMANGEOL relaunch and pediatric endocrinology growth. FY 2026 revenue guidance raised to over $145M. Adjusted EBITDA was $16.2M (43% margin). ASN-001 licensing and study costs total $7M. Non-GAAP net income was $14.3M ($0.43/diluted share).
2 min read